| Name | Title | Contact Details |
|---|---|---|
Raj Suchak |
Chief Technology Officer | Profile |
Based in Austin, Texas, TimberTown Specialty Building Products supplies high quality lumber and building materials for a wide variety of residential and commercial projects. Our products range from high-end exotic hardwoods, softwoods and composites; often specially milled for different applications. The types of projects we supply can be as simple as a small residential outdoor cedar deck, to the very complex hardwood siding for a multi-million dollar custom home or a rooftop patio on a downtown high-rise. With such a large and diverse client base, we excel in providing exceptional service for contractors and commercial builders, architects, designers and their clients.
DuBois Chemicals, Inc. is a prominent specialty chemical supplier with a history that dates back to 1920. Based in Hamilton, Ohio, the company is dedicated to providing innovative and economical solutions across various industries. DuBois focuses on delivering custom chemical solutions that enhance efficiency and reliability in industrial processes, emphasizing customer satisfaction and sustainability. The company offers a diverse product portfolio that includes cleaning and process solutions for general manufacturing, specialized chemicals for the pulp and paper industry, transportation cleaning solutions, and water treatment chemicals. With a significant facility in Cincinnati, Ohio, DuBois employs over 150 staff members, including scientists and customer service representatives, and has a strong sales team of over 400 representatives serving customers throughout North America. DuBois Chemicals demonstrates financial strength with revenues ranging from $100 million to $1 billion, allowing for continued investment in research and development.
Sterling Bank "Your one-customer bank" is a full service national commercial bank in Nigeria which has evolved from the nations pre-eminent investment banking institution to a fully-fledged commercial bank. Sterling Bank prides itself in its purpose to ‘Enrich Lives, and reflects its overall business aspirations in its vision to ‘be the financial institution of choice. This it plans to achieve by (mission) ‘delivering solutions that enhance stakeholders value, through four core values: Customer focus, Integrity, Teamwork and Excellence (CITE). With strong Corporate Governance, the bank has a vision-led and values-driven experienced team with a track record of delivery. With over 3,000 professional employees, Sterling Bank has about 1,000,000 active customers, and operates from 189 business offices, about 776 ATMs and more than 3,000 POS terminals across Nigeria. Sterling Bank operates with a three-pronged market focus. Its business lines and operations are structured around these segments; Retail and Consumer market, Commercial and Institutional market and Corporate and Investment market. Our purpose of enriching lives is what drives us to support society. We have contributed positively to our environment through several initiatives such as #STEM (Sterling Environmental Makeover), Meet The Executives, Get Ready For Work, Sketchamania, and several other interventions within other areas especially Education.
IVP, a public listed company, was founded in 1929. We started with vegetable oils and later diversified into an array of fields We were originally part of the TATA Group but later got acquired by the Allanas. Today we are an integral part of the Allana Group. We were the first company to manufacture Foundry Chemicals in India in technical collaboration with M/s Ashland Inc way back in 1965 Our manufacturing plants at Tarapur and Bangalore have a combined annual capacity of approximately 50,000 MT per annum catering to the foundry, composites, refractory & insulation industries in India and neighboring countries.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.